174 related articles for article (PubMed ID: 15094933)
1. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Clin Appl Thromb Hemost; 2004 Apr; 10(2):133-41. PubMed ID: 15094933
[TBL] [Abstract][Full Text] [Related]
2. Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
J Thromb Thrombolysis; 2004 Dec; 18(3):177-85. PubMed ID: 15815879
[TBL] [Abstract][Full Text] [Related]
3. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
[TBL] [Abstract][Full Text] [Related]
4. Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients.
Sardo MA; Mandraffino G; Riggio S; D'Ascola A; Alibrandi A; Saitta C; Imbalzano E; Castaldo M; Cinquegrani M; Saitta A
Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):933-8. PubMed ID: 20497421
[TBL] [Abstract][Full Text] [Related]
5. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
[TBL] [Abstract][Full Text] [Related]
6. Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Abdel-Zaher AO; Elkoussi AE; Abudahab LH; Elbakry MH; Elsayed EA
Fundam Clin Pharmacol; 2014 Jun; 28(3):237-48. PubMed ID: 23488690
[TBL] [Abstract][Full Text] [Related]
7. Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
J Hum Hypertens; 2005 Jul; 19(7):551-7. PubMed ID: 15829999
[TBL] [Abstract][Full Text] [Related]
8. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Kang MH; Ahn TH; Choi IS; Shin EK
Circulation; 2004 Dec; 110(24):3687-92. PubMed ID: 15569835
[TBL] [Abstract][Full Text] [Related]
9. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
Han SH; Koh KK; Quon MJ; Lee Y; Shin EK
Atherosclerosis; 2007 Jan; 190(1):205-11. PubMed ID: 16500662
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.
Sohma R; Inoue T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Arikawa T; Hikichi Y; Sanada S; Asanuma H; Kitakaze M; Node K
J Cardiol; 2012 Jan; 59(1):91-6. PubMed ID: 21925839
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats.
Strawn WB; Gallagher PE; Tallant EA; Ganten D; Ferrario CM
J Cardiovasc Pharmacol; 1999 Mar; 33(3):341-51. PubMed ID: 10069667
[TBL] [Abstract][Full Text] [Related]
13. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Hum Hypertens; 2002 Aug; 16(8):539-47. PubMed ID: 12149659
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
[TBL] [Abstract][Full Text] [Related]
15. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.
Husarek KE; Katz PS; Trask AJ; Galantowicz ML; Cismowski MJ; Lucchesi PA
Vascul Pharmacol; 2016 Jan; 76():28-36. PubMed ID: 26133668
[TBL] [Abstract][Full Text] [Related]
17. Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus.
Shouzu A; Nomura S; Omoto S; Hayakawa T; Nishikawa M; Iwasaka T
Clin Appl Thromb Hemost; 2004 Apr; 10(2):167-73. PubMed ID: 15094937
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
[TBL] [Abstract][Full Text] [Related]
19. Synergism of simvastatin with losartan prevents angiotensin II-induced cardiomyocyte apoptosis in vitro.
Xu J; Lü XW; Huang Y; Zhu PL; Li J
J Pharm Pharmacol; 2009 Apr; 61(4):503-10. PubMed ID: 19298698
[TBL] [Abstract][Full Text] [Related]
20. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
